Fibroblast Growth Factor: A Literature Course

This course walks through what the published literature says about fibroblast growth factors (FGFs), one module at a time. It is descriptive: it summarises models, endpoints and reported findings from a defined set of papers, and it flags where those papers stop. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment.

Module 1 — What Fibroblast Growth Factor Is, and How It Has Been Studied

"Fibroblast growth factor" is not one molecule. It is the name of a protein family whose individual members are numbered, and the published reviews treat each number as a separate subject with its own genetics, receptors and tissue distribution. Dedicated review articles exist for FGF6, FGF10, FGF21, FGF13 and FGF22, all published in the journal Differentiation as short profiles of single family members.

Class and origin

FGFs are endogenous secreted or intracellular signalling proteins encoded by human genes, not synthetic research peptides in the usual sense. They are considerably larger than the short chains often discussed under the word "peptide": they are full proteins that fold into a characteristic β-trefoil core, which is why protein-engineering papers such as the computer-assisted stabilisation study of FGF-18 focused on thermal and structural stability rather than on sequence length.

Forms described in the literature

• Paracrine FGFs — locally acting growth factors. The FGF10 review described this member in the context of epithelial–mesenchymal signalling during organ development, and the FGF6 review described a member with a notably muscle-associated expression pattern.
• Endocrine FGFs — members that circulate and act at a distance. The FGF21 review placed FGF21 in this metabolic, hormone-like group, and clinical chemistry work on FGF-23 in maintenance hemodialysis patients treated FGF-23 as a measurable circulating analyte.
• Intracellular FGFs — members that are not conventional secreted ligands. The FGF13 review covered a member of this intracellular subgroup.
• Synapse-associated members — the FGF22 review described a member studied in the nervous system.
• Basic FGF (bFGF/FGF2) — the classical laboratory growth factor, used in the affibody-mediated controlled-release study as the payload of a delivery system, and detected immunochemically in human tissue in a study of cholesteatoma matrix.

How the family has been studied

Across the verified set, four research styles dominate: narrative single-gene reviews (FGF6, FGF10, FGF13, FGF21, FGF22); human biomarker studies that measured a circulating FGF, as in the FGF21 and obstructive sleep apnea cohort analysis; protein and delivery engineering, as in the FGF-18 stabilisation work and the FGF2 affibody release system; and receptor-directed targeting, as in the construction of immunoliposomes against fibroblast growth factor receptor 3.

Limits of the evidence (Module 1)

The papers in this set are not a systematic map of the family. Several members have no representation here at all, the single-member reviews are narrative rather than quantitative, and none of them establishes a dosing framework, a route of administration or a human use case for an FGF given as an exogenous compound.

Module 2 — Mechanism as Described in the Literature

The general mechanism described in FGF literature is receptor tyrosine kinase signalling: a secreted FGF engages one of the FGF receptors, usually with a heparan-sulfate or co-receptor requirement, and the activated receptor triggers intracellular cascades that change proliferation, differentiation or metabolic gene expression. The verified set illustrates this at the level of individual members rather than restating it as a single pathway diagram.

Receptor-dependent signalling

Developmental signalling by secreted members is the framing used in the FGF10 review, which described FGF10 as a mesenchymal signal acting on epithelium during organogenesis, and in the FGF6 review, which described a member studied in skeletal-muscle biology. The FGF22 review described a member studied for its role in the nervous system, where FGF signalling has been examined in synaptic organisation rather than in bulk tissue growth.

Endocrine and metabolic signalling

The FGF21 review described FGF21 as an endocrine member with metabolic functions, which is the biological premise behind biomarker studies such as the analysis reporting circulating FGF21 as an independent predictor of prevalent and incident obstructive sleep apnea. Similarly, the mineral-metabolism role of FGF-23 is the premise for measuring it in dialysis populations, as researchers did in the Indian maintenance hemodialysis study.

Receptor-independent (intracellular) mechanism

Not every FGF works through a receptor on the cell surface. The FGF13 review covered a member of the intracellular FGF subgroup, whose described functions are not those of a classical extracellular ligand — an important qualifier when the family name is used loosely as a synonym for "growth factor injection".

Mechanism as an engineering problem

Two papers treated FGF mechanism from the delivery side. The affibody-mediated controlled-release study reported a strategy in which an affibody-based system governed the release of FGF2, and the FGF-18 paper reported computer-assisted redesign aimed at stabilising the protein. The receptor side has also been used as an address rather than a switch: researchers built immunoliposomes targeting FGFR3 to direct a carrier to receptor-expressing cells.

Limits of the evidence (Module 2)

These mechanistic descriptions are member-specific and mostly preclinical or in vitro. None of the cited papers demonstrated that a mechanism described for one family member transfers to another, and none linked a mechanistic step to a clinical outcome in humans.

Module 3 — Reported Outcomes, Study by Study

The table below summarises what each primary study used as its model and what the authors reported. Nothing in this table should be read as a benefit claim; several entries are descriptive or biomarker findings rather than intervention results.

The five Differentiation member profiles — FGF6, FGF10, FGF21, FGF13 and FGF22 — contribute background rather than outcomes: they summarise gene, expression and function for one member each and do not report new experimental endpoints.

Limits of the evidence (Module 3)

The one longevity-type result in this set came from an invertebrate model (PMID 32309367), and the two human datasets were observational measurements of an endogenous protein, not trials of an administered product (PMID 36798439, PMID 28182071). Association does not establish causation, and no cited study compared an FGF against a placebo in people.

Module 4 — Fibroblast Growth Factor Side Effects: What Studies Report

The verified set does not contain a safety trial, an adverse-event table or a tolerability analysis for any FGF given to humans. What it does contain are findings in which FGF signalling appeared in the context of disease rather than benefit — the closest published analogue to a risk signal.

• Presence in a proliferative lesion. The immunochemical study reported that basic fibroblast growth factor was localised within cholesteatoma matrix, a destructive lesion of the middle ear (PMID 30808433), which is why the same growth-factor biology that supports repair is also studied in abnormal tissue growth.
• Receptor signalling as an oncology target. Researchers constructed immunoliposomes directed at FGFR3 precisely because that receptor is of interest as a therapeutic target, and the study characterised the targeted carrier rather than any systemic FGF exposure (PMID 31535232).
• Elevated circulating FGF in disease states. The dialysis study measured FGF-23 in maintenance hemodialysis patients, where the protein is examined as part of disordered mineral metabolism rather than as a therapeutic agent (PMID 28182071). In a separate population, higher circulating FGF21 was reported as an independent predictor of prevalent and incident obstructive sleep apnea (PMID 36798439), meaning the analyte tracked with a condition rather than with improvement.
• Instability as a practical hazard. Two engineering papers implied that native FGF proteins are difficult to handle: one reported computer-assisted stabilisation of FGF-18 (PMID 37920818) and another reported an affibody-based system to control FGF2 release (PMID 36087800). Neither study reported clinical toxicity.

Limits of the evidence (Module 4)

No cited paper enrolled human volunteers to receive an FGF, so there is no reported incidence of any adverse event, no dose–toxicity relationship and no long-term follow-up in this set. Absence of reported harm in these papers is a consequence of study design, not evidence of safety.

Module 5 — Pharmacokinetics Where Data Exist

No paper in the verified set reported human pharmacokinetic parameters — no half-life, clearance, bioavailability or exposure curve. The pharmacokinetic theme appears only indirectly, through work on stability and release.

• The FGF2 controlled-release study reported an affibody-mediated method for governing how the growth factor was released, an approach used when a protein's residence time at a site is the limiting factor.
• The FGF-18 study reported computational redesign intended to stabilise the protein, addressing the physical fragility that complicates formulation.
• Biomarker studies measured endogenous circulating concentrations rather than administered exposure, both for FGF21 (PMID 36798439) and for FGF-23 (PMID 28182071).

Limits of the evidence (Module 5)

Because none of these papers administered a defined amount of an FGF to a human and sampled blood over time, this course states no dose, no interval and no exposure figure. Stability and release data from laboratory systems do not translate into pharmacokinetic parameters in people.

Module 6 — Regulatory Status, Stated Factually

Regulatory status differs by molecule, by country and by intended use, and the verified literature set does not itself address regulation. The following points are general regulatory facts rather than study findings.

1. Research-use-only (RUO) material. Recombinant FGF proteins are widely sold to laboratories as reagents labelled for research use only. RUO labelling means the material has not been evaluated or authorised for diagnostic or therapeutic use in humans or animals.
2. Approved medicines versus research molecules. Some FGF-family proteins and FGF-receptor–directed drugs have been developed as regulated pharmaceuticals and evaluated through formal marketing-authorisation pathways; others, including most family members discussed in the reviews cited here, exist only as research proteins or clinical-stage candidates. A protein having a published literature base does not mean an approved product containing it exists.
3. Clinical-stage engineering. Work such as the FGF-18 stabilisation study and the FGF2 release study reflects the preformulation stage of development, which precedes any regulatory decision.
4. Compounding. In the United States, pharmacy compounding under sections 503A and 503B of the Food, Drug, and Cosmetic Act is limited to substances that meet statutory eligibility criteria, and large recombinant proteins generally fall outside the categories a compounding pharmacy may lawfully use. Eligibility lists and agency positions change over time.
5. Sport and clinical governance. Growth-factor products are treated as regulated substances in many sport and clinical contexts; the applicable rules are set by the relevant authority, not by the research literature.

Limits of the evidence (Module 6)

Regulatory classification is jurisdiction-specific and changes; nothing in this module is legal advice, and none of the cited papers evaluated regulatory status.

What the Studies Did Not Test

Reading the set as a whole, the gaps are as important as the findings:

• No human intervention data. No cited study administered an FGF to humans; the human data were observational measurements of endogenous protein (PMID 36798439, PMID 28182071).
• No dosing information. No amount, schedule, route or duration for any FGF appears in this set, so none is stated here.
• No cross-member generalisation. The member reviews describe distinct biology for FGF6, FGF10, FGF13, FGF21 and FGF22 (PMID 38626632, PMID 40139106), and none tested whether a finding for one applies to another.
• No long-term or cancer-risk follow-up. Although FGF signalling was studied in a proliferative lesion (PMID 30808433) and as a receptor target (PMID 31535232), no cited paper followed exposed subjects over time.
• No translation of the lifespan result. The lifespan and stress-tolerance findings were obtained in silkworm (PMID 32309367) and were not tested in mammals within this set.

Anyone comparing this summary against the primary sources should read the abstracts and full texts directly; this course paraphrases them and cannot replace them.

References

• Fibroblast Growth Factor 6 (Differentiation; research in biological diversity, 2024)
• Fibroblast growth factor 10 (Differentiation; research in biological diversity, 2024)
• Fibroblast growth factor 21 (Differentiation; research in biological diversity, 2024)
• Fibroblast growth factor 21 is an independent predictor of prevalent and incident obstructive sleep apnea (iScience, 2023)
• Fibroblast Growth Factor (FGF) 13 (Differentiation; research in biological diversity, 2024)
• Affibody-mediated controlled release of fibroblast growth factor 2 (Journal of Controlled Release, 2022)
• Fibroblast growth factor 22 (Differentiation; research in biological diversity, 2025)
• Computer-assisted stabilization of fibroblast growth factor FGF-18 (Computational and Structural Biotechnology Journal, 2023)
• Localisation of basic fibroblast growth factor in cholesteatoma matrix: an immunochemical study (The Journal of Laryngology and Otology, 2019)
• Fibroblast growth factor 21 prolongs lifespan and improves stress tolerance in the silkworm, Bombyx mori (Annals of Translational Medicine, 2020)
• Construction and characterization of immunoliposomes targeting fibroblast growth factor receptor 3 (AMB Express, 2019)
• Fibroblast growth factor-23 levels in maintenance hemodialysis patients in India (Indian Journal of Nephrology, 2017)